Literature DB >> 17609322

Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.

Diane M Citron1, Ellie J C Goldstein, C Vreni Merriam, Benjamin A Lipsky, Murray A Abramson.   

Abstract

As part of a United States-based multicenter clinical trial, conducted from 2001 to 2004, that compared ertapenem to piperacillin-tazobactam for the treatment of moderate-to-severe diabetic foot infections (DFIs), we obtained 454 pretreatment specimens from 433 patients. After debridement, the investigators collected wound specimens, mostly by curettage or biopsy, and sent them to the R. M. Alden Research Laboratory for aerobic and anaerobic culture. Among the 427 positive cultures, 83.8% were polymicrobial, 48% grew only aerobes, 43.7% had both aerobes and anaerobes, and 1.3% had only anaerobes. Cultures yielded a total of 1,145 aerobic strains and 462 anaerobic strains, with an average of 2.7 organisms per culture (range, 1 to 8) for aerobes and 2.3 organisms per culture (range, 1 to 9) for anaerobes. The predominant aerobic organisms were oxacillin-susceptible Staphylococcus aureus (14.3%), oxacillin-resistant Staphylococcus aureus (4.4%), coagulase-negative Staphylococcus species (15.3%), Streptococcus species (15.5%), Enterococcus species (13.5%), Corynebacterium species (10.1%), members of the family Enterobacteriaceae (12.8%), and Pseudomonas aeruginosa (3.5%). The predominant anaerobes were gram-positive cocci (45.2%), Prevotella species (13.6%), Porphyromonas species (11.3%), and the Bacteroides fragilis group (10.2%). Pure cultures were noted for 20% of oxacillin-resistant Staphylococcus aureus cultures, 9.2% of Staphylococcus epidermidis cultures, and 2.5% of P. aeruginosa cultures. Two or more species of Staphylococcus were present in 13.1% of the patients. Ertapenem and piperacillin-tazobactam were each active against >98% of the enteric gram-negative rods, methicillin-sensitive S. aureus, and anaerobes. Among the fluoroquinolones, 24% of anaerobes, especially the gram-positive cocci, were resistant to moxifloxacin; 27% of the gram-positive aerobes but only 6% of the members of the family Enterobacteriaceae were resistant to levofloxacin. Moderate-to-severe DFIs are typically polymicrobial, and almost half include anaerobes. Our antibiotic susceptibility results can help to inform therapeutic choices.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609322      PMCID: PMC2045270          DOI: 10.1128/JCM.00551-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  52 in total

1.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital.

Authors:  Ravisekhar Gadepalli; Benu Dhawan; Vishnubhatla Sreenivas; Arti Kapil; A C Ammini; Rama Chaudhry
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

3.  Bacteriological study of diabetic foot infections.

Authors:  Adel Abdulrazak; Zouheir Ibrahim Bitar; Abdullah Ayesh Al-Shamali; Lubna Ahmed Mobasher
Journal:  J Diabetes Complications       Date:  2005 May-Jun       Impact factor: 2.852

4.  Factors characterizing Staphylococcus epidermidis invasiveness determined by comparative genomics.

Authors:  Yufeng Yao; Daniel E Sturdevant; Amer Villaruz; Lin Xu; Qian Gao; Michael Otto
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

5.  Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection.

Authors:  G Pellizzer; M Strazzabosco; S Presi; F Furlan; L Lora; P Benedetti; M Bonato; G Erle; F de Lalla
Journal:  Diabet Med       Date:  2001-10       Impact factor: 4.359

6.  Outpatient management of uncomplicated lower-extremity infections in diabetic patients.

Authors:  B A Lipsky; R E Pecoraro; S A Larson; M E Hanley; J H Ahroni
Journal:  Arch Intern Med       Date:  1990-04

7.  Vertebral osteomyelitis and prosthetic joint infection due to Staphylococcus simulans.

Authors:  R R Razonable; D G Lewallen; R Patel; D R Osmon
Journal:  Mayo Clin Proc       Date:  2001-10       Impact factor: 7.616

8.  Virulence profiling of Streptococcus dysgalactiae subspecies equisimilis isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases.

Authors:  Mark R Davies; David J McMillan; Robert G Beiko; Vanessa Barroso; Robert Geffers; Kadaba S Sriprakash; Gursharan S Chhatwal
Journal:  Clin Infect Dis       Date:  2007-04-19       Impact factor: 9.079

9.  Clinically significant coagulase-negative staphylococci: identification and resistance patterns.

Authors:  K Refsahl; B M Andersen
Journal:  J Hosp Infect       Date:  1992-09       Impact factor: 3.926

10.  Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact.

Authors:  A Hartemann-Heurtier; J Robert; S Jacqueminet; G Ha Van; J L Golmard; V Jarlier; A Grimaldi
Journal:  Diabet Med       Date:  2004-07       Impact factor: 4.359

View more
  115 in total

1.  In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Authors:  Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Longitudinal shift in diabetic wound microbiota correlates with prolonged skin defense response.

Authors:  Elizabeth A Grice; Evan S Snitkin; Laura J Yockey; Dustin M Bermudez; Kenneth W Liechty; Julia A Segre
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

Review 3.  Paraoxonases as protective agents against N-acyl homoserine lactone - producing pathogenic microorganisms.

Authors:  Bogdan Nicolae Manolescu
Journal:  Maedica (Bucur)       Date:  2013-03

4.  Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.

Authors:  Jolanta Majcher-Peszynska; Marko Sass; Sora Schipper; Viktor Czaika; Andreas Gussmann; Ralf Lobmann; Ralf G Mundkowski; Christoph Luebbert; Peter Kujath; Bernhard R Ruf; Horst Koch; Wolfgang Schareck; Ernst Klar; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2010-09-25       Impact factor: 2.953

Review 5.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

6.  Ceftobiprole: First reported experience in osteomyelitis.

Authors:  A Macdonald; G Dow
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 7.  The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey.

Authors:  M Hatipoglu; M Mutluoglu; G Uzun; E Karabacak; V Turhan; B A Lipsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-23       Impact factor: 3.267

Review 8.  MRSA and diabetic foot wounds: contaminating or infecting organisms?

Authors:  Frank L Bowling; Edward B Jude; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

9.  From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.

Authors:  C Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 10.  The treatment of diabetic foot infections: focus on ertapenem.

Authors:  Michael Edmonds
Journal:  Vasc Health Risk Manag       Date:  2009-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.